Development of GVHD after HCT and clinical response
ID no. . | Previous therapies . | GVHD grade . | GVHD site . | GVHD, d . | CSA stop, d . | GVHD treatment . | CEA before transplantation/at GVHD onset or d + 100, ng/mL . | CEA expression by tumor cells* . | Clinical response† . | HLA-A*0201 . | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GVHD involvement | |||||||||||
| 1 | De Gramont, Tomudex, FOLFOX, CPT-11, MMC | II | GI | 49 | 150 | PDN | 110/160 | ND | SD† | NEG | |
| 2 | 5FU-VP 16, liver surgery, FOLFOX | III | GI | 110 | 94 | CSA + PDN | 2/6† | ND | MR | NEG | |
| 4 | FOLFIRI, FOLFOX | II | Skin, GI, liver | 41 | 180 | PDN | 8/9 | ND | None | NEG | |
| 8 | FOLFOX, FOLFIRI, De Gramont, MMC | IV | GI, liver | 88 | 86 | CSA + PDN, infiximab | 2/3 | +++ | SD† | POS | |
| 10 | FOLFOX, liver surgery | III | Skin, GI | 121 | 110 | CSA + PDN, infliximab | 56/480 | ++ | None | NEG | |
| 11 | FOLFOX, liver surgery, FOLFIRI | II | GI, liver | 210 | 140 | CSA | 607/61 | +++ | PR | POS | |
| 12 | FOLFOX, surgery, FOLFIRI | III | Skin, GI | 120 | 100 | PDN + CSA | 18/36 | +++ | None | POS | |
| 15 | FOLFIRI, CPT-11, 5FU, MMC, cetuximab | II | Skin, GI | 51 | NA | PDN | 2112/1800 | ND | None | NEG | |
| No GVHD involvement | |||||||||||
| 3 | FOLFOX, liver surgery | 0 | NA | NA | 91 | NA | 90/100 | ND | None | POS | |
| 5 | FOLFOX | 0 | NA | NA | 118 | NA | 8/9 | ++ | SD† | NEG | |
| 6 | FOLFIRI, FOLFIRI | 0 | NA | NA | 85 | NA | 365/780 | ND | None | NEG | |
| 7 | FOLFIRI, FOLFOX | 0 | NA | NA | NA | NA | 90/170 | ND | None | POS | |
| 9 | FOLFOX | 0 | NA | NA | 90 | NA | 1/2 | ++ | None | POS | |
| 13 | FOLFOX, FOLFIRI, liver criosurgery, MMC | 0 | NA | NA | 88 | NA | 370/ND | ND | None | NEG | |
| 14 | FOLFOX, FOLFIRI, De Gramont | 0 | NA | NA | NA | NA | 2380/ND | ND | None | NEG | |
ID no. . | Previous therapies . | GVHD grade . | GVHD site . | GVHD, d . | CSA stop, d . | GVHD treatment . | CEA before transplantation/at GVHD onset or d + 100, ng/mL . | CEA expression by tumor cells* . | Clinical response† . | HLA-A*0201 . | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GVHD involvement | |||||||||||
| 1 | De Gramont, Tomudex, FOLFOX, CPT-11, MMC | II | GI | 49 | 150 | PDN | 110/160 | ND | SD† | NEG | |
| 2 | 5FU-VP 16, liver surgery, FOLFOX | III | GI | 110 | 94 | CSA + PDN | 2/6† | ND | MR | NEG | |
| 4 | FOLFIRI, FOLFOX | II | Skin, GI, liver | 41 | 180 | PDN | 8/9 | ND | None | NEG | |
| 8 | FOLFOX, FOLFIRI, De Gramont, MMC | IV | GI, liver | 88 | 86 | CSA + PDN, infiximab | 2/3 | +++ | SD† | POS | |
| 10 | FOLFOX, liver surgery | III | Skin, GI | 121 | 110 | CSA + PDN, infliximab | 56/480 | ++ | None | NEG | |
| 11 | FOLFOX, liver surgery, FOLFIRI | II | GI, liver | 210 | 140 | CSA | 607/61 | +++ | PR | POS | |
| 12 | FOLFOX, surgery, FOLFIRI | III | Skin, GI | 120 | 100 | PDN + CSA | 18/36 | +++ | None | POS | |
| 15 | FOLFIRI, CPT-11, 5FU, MMC, cetuximab | II | Skin, GI | 51 | NA | PDN | 2112/1800 | ND | None | NEG | |
| No GVHD involvement | |||||||||||
| 3 | FOLFOX, liver surgery | 0 | NA | NA | 91 | NA | 90/100 | ND | None | POS | |
| 5 | FOLFOX | 0 | NA | NA | 118 | NA | 8/9 | ++ | SD† | NEG | |
| 6 | FOLFIRI, FOLFIRI | 0 | NA | NA | 85 | NA | 365/780 | ND | None | NEG | |
| 7 | FOLFIRI, FOLFOX | 0 | NA | NA | NA | NA | 90/170 | ND | None | POS | |
| 9 | FOLFOX | 0 | NA | NA | 90 | NA | 1/2 | ++ | None | POS | |
| 13 | FOLFOX, FOLFIRI, liver criosurgery, MMC | 0 | NA | NA | 88 | NA | 370/ND | ND | None | NEG | |
| 14 | FOLFOX, FOLFIRI, De Gramont | 0 | NA | NA | NA | NA | 2380/ND | ND | None | NEG | |
De Gramont indicates 400 mg/m2 fluorouracil, 600 mg/m2 fluorouracil, and 200 mg/m2 leucovorin; Tomudex, 4 mg/m2; FOLFOX, 100 mg/m2 oxaliplatin, 400 mg/m2 fluorouracil, 600 mg/m2 fluorouracil, and 200 mg/m2 leucovorin; CPT-11, 100 mg/m2 Irinotecan; MMC, 10 mg/m2 mytomicin-C; 5FU/VP16, 500 mg/m2 fluorouracil, 200 mg/m2 leucovorin, and 100 mg/m2 VP 16; FOLFIRI, 180 mg/m2 irinotecan, 400 mg/m2 fluorouracil, 600 mg/m2 fluorouracil, and 200 mg/m2 leucovorin; cetuximab, 400 mg/m2 on day 1, 250 mg/m2 on days 8, 14, 21; PDN, prednisone; ND, not determined; and NA, not applicable.
CEA expression on tumor biopsies as detected by immunohistochemistry. ++ indicates moderately reactive; +++, strongly reactive tumor cells (“Patients, materials, and methods”)
SDs that lasted more than 90 days were considered as relevant clinical responses; short lasting stable disease were excluded